Pre-Made Onercept Biosimilar, Recombinant Protein targeting TNF: Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tumor necrosis factor (TNF) is a proinflammatory cytokine that plays a pivotal part in the pathogenesis of Crohn¡¯s disease (CD). Anti-TNF therapies have been developed for the treatment of CD. Onercept is a recombinant human soluble p55 tumor necrosis factor binding protein for the potential treatment of a number of disorders, including Crohn’s disease, psoriasis and psoriatic arthritis.